Merck to Buy Idenix for $3.85 Billion — 6th Update – NASDAQ
KVAL |
Merck to Buy Idenix for .85 Billion — 6th Update
NASDAQ Merck & Co.'s.85 billion deal to acquire a developer of hepatitis C drugs underscores the pharmaceutical industry's bet that improved medicines for the liver disease represent a large, long-term market opportunity. Merck agreed to acquire Idenix … Notable Winners: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Orexigen … Dollar General Corp. (NYSE:DG) and Idenix Pharmaceuticals Inc (NASDAQ:IDIX … |
